Loading...
Loading...
BFRI| Name | Value |
|---|---|
| Revenues | 7,839.0K |
| Cost of Revenue | 4,342.0K |
| Gross Profit | 3,497.0K |
| Operating Expense | 8,568.0K |
| Operating I/L | -5,071.0K |
| Other Income/Expense | 4,834.0K |
| Interest Income | 24.0K |
| Pretax | -237.0K |
| Income Tax Expense | 20.0K |
| Net Income/Loss | -257.0K |
Biofrontera Inc. is a biopharmaceutical company specializing in the commercialization of pharmaceutical products for dermatological conditions in the United States. Its flagship product, Ameluz, is a prescription drug used in combination with the RhodoLED lamp series for photodynamic therapy to treat actinic keratosis. Additionally, the company offers Xepi, a prescription cream for impetigo treatment. Biofrontera generates revenue through the sale of these prescription drugs and medical devices, catering to the needs of patients with dermatological conditions.
